中华介入放射学电子杂志 ›› 2014, Vol. 02 ›› Issue (01) : 11 -14. doi: 10.3877/cma j.issn.2095-5782.2014.01.004 × 扫一扫
肿瘤介入
收稿日期:
出版日期:
通信作者:
Ye Sheng1, Qingquan Zu1, Sheng Liu1,†(), Zhengqiang Yang1, Chungao Zhou1, Jinguo Xia1, Linbo Zhao1, Yaoliang Feng1, Haibin Shi1
Received:
Published:
Corresponding author:
盛晔, 祖庆泉, 刘圣, 杨正强, 周春高, 夏金国, 赵林波, 冯耀良, 施海彬. 观察海藻酸钠微球栓塞治疗肝细胞癌的近期疗效[J/OL]. 中华介入放射学电子杂志, 2014, 02(01): 11-14.
Ye Sheng, Qingquan Zu, Sheng Liu, Zhengqiang Yang, Chungao Zhou, Jinguo Xia, Linbo Zhao, Yaoliang Feng, Haibin Shi. Short-term efficacy of embolization with sodium alginate microspheres in patients with hepatocellular carcinoma[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2014, 02(01): 11-14.
目的
探讨海藻酸钠微球（KMG） 经肝动脉栓塞治疗肝细胞癌（HCC） 的近期临床疗效。
方法
回顾性分析应用KMG经肝动脉栓塞治疗的54 例HCC 患者的临床资料， 分析其相关不良反应、 并发症及肿瘤的近期疗效。
结果
所有患者均成功行栓塞治疗， 术后不良反应包括： 肝区疼痛66.67% （36/54） ， 发热55.56% （30/54） ， 恶心、 呕吐27.78% （15/54） ， 无严重并发症发生；22 例HCC 患者合并肝动脉门静脉分流（APS） 或肝动脉肝静脉分流（AVS） ； 术后2 个月CT或MR复查， 并测量肿瘤大小， 按改良的实体瘤疗效评价（RECIST） 标准评价： 部分缓解29.63% （16/54） ，稳定57.41% （31/54） ， 进展12.96% （7/54） 。
结论
KMG栓塞治疗HCC 是安全的， 近期疗效显著。
Objective
To investigate the short-term efficacy of embolization with sodium alginate microspheres（KMG）for treatment of hepatocellular carcinoma（HCC）.
Methods
Fifty-four patients with HCC underwent TACE/TAE with KMG. Tumor responses，complications and adverse reactions related to embolization were analyzed.
Results
TACE/TAE was successfully accomplished in all patients.The common adverse reactions after embolization including abdominal pain（36/54，66.67%），fever（30/54，55.56%），nausea and vomiting（15/54，27.78%）.No severe complication occurred.Twenty-two HCC patients also had arterioportal shunts（APS）or arteriovenous shunts（AVS）.According to modified response evaluation criteria in solid tumors（RECIST）criteria，the two months follow-up results are as follows：29.63% （16/54）with partial response，57.41% （31/54）with stable disease，and 12.96% （7/54）with progressive disease，respectively.
Conclusions
Embolization with using of KMG is a safe and feasible treatment for HCC with remarkable short-term efficacy.